|
May 23
|
Exploring High Growth Tech Stocks In The US This May 2025
|
|
May 22
|
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
|
|
May 19
|
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 17
|
Exploring US High Growth Tech Stocks
|
|
Apr 16
|
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
|
|
Feb 25
|
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
|
|
Feb 13
|
Is Legend Biotech (LEGN) the Best Mid-Cap Growth Stock to Buy According to Analysts?
|
|
Feb 13
|
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?
|
|
Oct 16
|
Is Legend Biotech Corporation (LEGN) the Most Promising Biotech Stock According to Hedge Funds?
|
|
Sep 14
|
Legend Biotech Corporation (LEGN): Among Hedge Funds’ Top Biotech Stock Picks
|
|
Sep 12
|
Here’s Why TimesSquare Capital Management U.S. Focus Growth Strategy Removed Legend Biotech Corporation (LEGN) from its Portfolio
|
|
Jul 29
|
Is Legend Biotech Corporation (LEGN) a Good Growth Stock to Buy?
|
|
Jul 26
|
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
|
|
Jun 24
|
Does Legend Biotech (LEGN) Have a Long Runway for Growth?
|
|
May 14
|
Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...
|
|
May 14
|
Q1 2024 Legend Biotech Corp Earnings Call
|
|
May 13
|
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
|
|
May 9
|
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
|
|
Apr 22
|
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
Apr 11
|
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
|